OBJECTIVE:To evaluate the safety of several pretreatment protocols of paclitaxel liposome as a chemotherapy for upper gastrointestinal tumor.METHODS:26 patients with upper gastrointestinal tumors receiving paclitaxel liposome in combination with other chemotherapeutics were enrolled.The patients were injected intravenously with dexamethasone 10 mg (i ) or dexamethasone 5 mg(ii ) or prednisolone 40 mg(iii ) 30 minutes prior administration of paclitaxel liposome,or treated with oral dexamethasone at a dose of 6 mg(i ),4.5 mg(ii ) or 2.25 mg(iii ) 12 hours or 2 hours prior administration of paclitaxel liposome.RESULTS:Chemotherapy- induced toxic adverse reactions manifested as gradeⅠ～Ⅱleucopenia,anemia, nausea and vomiting,but recovered after symptomatic treatment.Pretreatment- related adverse reactions manifested as insomnia, hyperglycemia,fatigue and vertigo,but no allergic shock or treatment- related death occurred.CONCLUSION:Intravenous injection of prednisolone 40 mg 30 minutes prior administration of paclitaxel liposome or oral administration of dexamethasone 2.25 mg 12 hours and 2 hours prior administration of paclitaxel liposome are preferable pretreatment methods of paclitaxel liposome.

Objective: Non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-activating mutations have higher response rate and more prolonged survival following treatment with single-agent EGFR tyrosine kinase inhibitor (EGFR-TKI) compared with patients with wild-type EGFR. However, all patients treated with reversible inhibitors develop acquired re-sistance over time. The mechanisms of resistance are complicated. The lack of established therapeutic options for patients after a failed EGFR-TKI treatment poses a great challenge to physicians in managing this group of lung cancer patients. This study evaluates the in-fluence of EGFR-TKI retreatment following chemotherapy after failure of initial EGFR-TKI within at least six months on NSCLC pa-tients. Methods:The data of 27 patients who experienced treatment failure from their initial use of EGFR-TKI within at least 6 months were analyzed. After chemotherapy, the patients were retreated with EGFR-TKI (gefitinib 250 mg qd or erlotinib 150 mg qd), and the tumor progression was observed. The patients were assessed for adverse events and response to therapy. Targeted tumor lesions were as-sessed with CT scan. Results:Of the 27 patients who received EGFR–TKI retreatment, 1 (3.7%) patient was observed in complete re-sponse (CR), 8 (29.6%) patients in partial response (PR), 14 (51.9%) patients in stable disease (SD), and 4 (14.8%) patients in progres-sive disease (PD). The disease control rate (DCR) was 85.2%(95%CI=62%-94%). The median progression-free survival (mPFS) was 6 months (95%CI=1-29). Of the 13 patients who received the same EGFR-TKI, 1 patient in CR, 3 patients in PR, 8 patients in SD, and 2 patients in PD were observed. The DCR was 84.6%, and the mPFS was 5 months. Of the 14 patients who received another EG-FR-TKI, 0 patient in CR, 6 patients in PR, 6 patients in SD, and 2 patients in PD were observed. The DCR was 85.7%, and the mPFS was 9.5 months. Significant difference was found between the 2 groups in progression-free survival but not in response rate or disease control rate. Conclusion:Retreatment of EGFR-TKIs can be considered an option after failure of chemotherapy for patients who were
previously controlled by EGFR-TKI treatment.